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Objective To examine the changes in the prevalence of, and the
factors associated with, the use of emergency contraception (EC)
in Britain between 2000 and 2010, spanning the period of
deregulation and increase in pharmacy supply.
Design Cross-sectional probability sample surveys.
Setting and population British general population.
Methods Data were analysed from the second and third British
National Surveys of Sexual Attitudes and Lifestyles (Natsal),
undertaken in 1999–2001 and 2010–12. Univariate and logistic
regression analyses were used to measure change in EC use
amongst sexually active women aged 16–44 years not intending
pregnancy.
Main outcome measures Prevalence of EC use and factors
associated with use.
Results Of the 5430 women surveyed in 1999–2001 and the 4825
women surveyed in 2010–12, 2.3 and 3.6%, respectively, reported
using EC in the year prior to interview (P = 0.0019 for change
over time). The prevalence of EC use increased amongst single
women and those with higher educational attainment (adjusted
odds ratio, aOR 1.51; 95% confidence interval, 95% CI 1.04–2.20;
P = 0.0308). Increases in EC use were generally greater among
women without behavioural risk factors, such as those with no
history of abortion within 5 years (aOR 1.57; 95% CI 1.17–2.12;
P = 0.0029), or those whose first heterosexual intercourse
occurred after the age of 16 years (aOR 1.68; 95% CI 1.21–2.35;
P = 0.0021). The increase in EC use was also more marked
among women usually accessing contraception from retail sources
than among those doing so from healthcare sources, which may
reflect a use of condoms amongst EC users.
Conclusion The increase in EC use among women in Britain in
the first decade of the 21st century was associated with some, but
not all, risk factors for unplanned pregnancy. Advice and
provision may need to be targeted at those at highest risk of
unplanned pregnancy.
Keywords Emergency contraception, pharmacy access, risk
factors, sexual behaviour, unplanned pregnancy.
Tweetable abstract Despite pharmacy access, only a small rise in
emergency contraception use has been seen in Britain over
10 years.
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Introduction
Emergency contraception (EC), including oral and
intrauterine methods, occupies a unique position amongst
contraceptive methods, in that it can be used after sex to
prevent pregnancy.1 EC use has been promoted as a
component of strategies to reduce unintended pregnancy.2,3
EC use can be considered a marker of risky sexual beha-
viour, as it indicates exposure to unprotected sex or a fail-
ure in contraceptive method. Although the impact of EC
use on unintended pregnancy rates at a population level
has not yet been established,4 at the individual level, for
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women seeking to avert an unintended pregnancy after
unprotected intercourse, trial data indicate that intrauterine
devices will prevent 99% of pregnancies,5 and that oral EC
prevents around two-thirds of pregnancies if commenced
within 24 hours.6–8
Access to oral EC has changed dramatically in the UK
in the last 15 years.9 Major changes were facilitated by the
development of a progestogen-only formulation containing
levonorgestrel, which is both safe to use and has no signif-
icant contraindications. As a consequence, the levonorges-
trel formulation was deregulated and became available
over the counter (OTC) from pharmacies without pre-
scription in the UK in 2001, but prior to that some
National Health Service (NHS) areas had already enabled
pharmacy access via a Patient Group Direction. Further-
more, in 2009, ulipristal acetate, a selective progesterone
receptor modulator, was licensed for EC use with efficacy
demonstrated up to 120 hours after unprotected sexual
intercourse or contraceptive failure.10 It became accessible
only on prescription in the UK until April 2015 when the
European Medicines Agency reviewed the safety data and
changed its status to an OTC medication.11 Emergency
copper intrauterine devices continue to be available free at
the point of access through community family planning
and general practice clinics, and although significantly
more reliable compared with pills,5 are less accessible as
they require insertion by a healthcare practitioner, with
same-day insertion being an additional challenge. In tan-
dem with these advances, public education advertisements
have informed women about the role of EC after unpro-
tected sex,12,13 but, at least in the first few years of the
OTC availability of levonorgestrel EC, the improved infor-
mation and access did not translate into increased
uptake.14
Data from the second and third British National Surveys
of Sexual Attitudes and Lifestyles (Natsal) permit an exami-
nation of sociodemographic and sexual lifestyle factors
associated with the reported use of EC among women resi-
dent in Britain. The two surveys were carried out in 1999–
2001 and 2010–12, respectively, before and after the dereg-
ulation of oral EC in Britain. In this paper we report a
change in the prevalence of use of EC between the surveys,
together with factors associated with use and their differ-
ences between the surveys.
Methods
To date, three Natsal probability sample surveys have been
carried out, approximately decennially: in 1990–1991 (Nat-
sal-1), in 1999–2001 (Natsal-2), and in 2010–12 (Natsal-3).
In this paper we used data from Natsal-2 and Natsal-3 to
examine trends in use of EC over time before and after the
deregulation of oral EC in Britain. In Natsal-2, 11 161
respondents (6399 women aged 16–44 years) were inter-
viewed, and participants resident in London were oversam-
pled. Natsal-3 interviewed 15 162 men and women aged
16–74 years (5842 women aged 16–44 years), with an over-
sampling of women aged 16–34 years to allow for a
detailed exploration of behaviours in the age group at high-
est risk of sexual health outcomes such as unplanned preg-
nancy. The unadjusted response rate in Natsal-2 was 63.1%
and the adjusted rate, taking account of over-sampling in
London, was 65.4%. The response rate for Natsal-3 was
57.7% and the cooperation rate was 65.8% (of the eligible
addresses contacted).
Detailed descriptions of the methodology for Natsal-2
and Natsal-3 have been published elsewhere.15–17 In all
three Natsal surveys, households were selected using strati-
fied probability sampling, from which one eligible individ-
ual, resident in Britain (England, Scotland, or Wales), was
selected at random and invited to participate. Participants
were interviewed in their own homes through a combina-
tion of face-to-face computer-assisted personal interviews
(CAPI) and computer-assisted self-interview (CASI), for
the more sensitive questions.
As in Natsal-2, in Natsal-3 we weighted the data to
adjust for the unequal probabilities of selection in terms of
age and the number of adults in the eligible age range at
an address. After application of these selection weights, the
sample was broadly representative of the British population
compared with 2011 census figures, although men and
London residents were slightly under-represented.17 There-
fore, we also applied a non-response post-stratification
weighting to correct for differences in gender, age, and
Government Office Region between the achieved sample
and the 2011 census.17–19 Natsal-2 was approved by the
research ethics committees of University College London
and the North Thames Multicentre (3 June 1998) and by
all of the local research ethics committees in Britain. The
Natsal-3 study was approved by the Oxfordshire research
ethics committee A (reference: 09/H0604/27) on
12 July 2010. Participants provided oral informed consent
for interviews.
Measures
In the CAPI component of the questionnaire, participants
who reported ever using any contraceptive method(s) were
asked which, if any, and including EC, they had used with
a partner in the past year. The wording of the question
enabled women to report using EC in Natsal-2 and using
the ‘morning-after pill’ and/or an emergency intrauterine
device (IUD) in Natsal-3. For comparability with Natsal-2,
Natsal-3 responses for the morning-after pill and emer-
gency IUD were combined to create a measure of overall
EC use in the past year. Other contraceptive method(s)
used in the past year were classified according to the most
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effective method reported. Methods with a typical-use fail-
ure rate (which includes incorrect and inconsistent use)
below 10% were classified as more effective (IUD,
intrauterine system, implant, injection, patch, and oral con-
traceptive pill).20 Those with a typical-use failure rate of
more than 10% were classified as less effective [condoms
(male and female), diaphragm, pessaries, gels, emergency
contraception, withdrawal, rhythm method, and no
method].20 Participants using any contraceptive method(s)
in the past year were shown a card listing different sources
of supplies and asked to indicate which source(s) they had
used in the past year. Participants could report multiple
sources. In analyses, sources accessed to obtain contracep-
tion were grouped as clinical [doctor or nurse in general
practice, genitourinary medicine (GUM)/family planning/
contraceptive or reproductive health clinic, or youth ser-
vices] or retail/other (pharmacy/chemist, website, petrol
station/supermarket/other shop, vending machine, or mail
order and other).
The information from the CASI questions was used to
calculate any sexually transmitted infection (STI) diagnosis
(chlamydia, gonorrhoea, syphilis, herpes, genital warts, tri-
chomonas, or non-gonococcal/non-specific urethritis) in
the past year. Ethnic origin was derived from the Office for
National Statistics harmonised question on ethnicity. The
index of multiple deprivation (IMD) was used as an area-
level measure of social status.21Educational attainment was
defined according to school leaving age and academic qual-
ifications obtained (individual level). Religiosity was
derived from self-reported current importance of religion
(important or very important) and frequency of attendance
at religious services or meetings (at least twice a year).
Average weekly alcohol consumption was derived from
average frequency of consumption in the last year and
average intake when drinking (excluding special occasions).
Gender-specific limits (>21 units for men and >14 units
for women) were used to define exceeding the recom-
mended average consumption.22
Statistical analyses
We used STATA 13.1 for complex survey analysis to incor-
porate the weighting, clustering, and stratification of the
Natsal data. We present descriptive statistics of the preva-
lence of use of EC in 1999–2001 and 2010–12 among
heterosexually active women aged 16–44 years (defined as
those reporting at least one partner of the opposite gender
in the past year). We used logistic regression to examine
change in the prevalence of EC use between 1999–2001
and 2010–12 by key sociodemographic characteristics,
average alcohol consumption, and key sexual behaviours.
We included interaction terms to test whether the magni-
tude of change in EC use between the two surveys differed
by key sociodemographic characteristics, average alcohol
consumption, and key sexual behaviours. All regression
analyses were adjusted for age. We used an a value of
0.05 in all analyses.
Results
Of the 6399 women interviewed for Natsal-2, 5462 (87%)
women reported at least one male partner in the past
year, of whom 5430 had complete data on EC use. The
number of women interviewed and included in the
denominator varies slightly from that reported in a previ-
ous publication of the profile of EC users from Natsal-2
(Black et al. Contraception 2006;74:309–312), as this analy-
sis is restricted to participants included in the core Natsal-
2 sample, and does not include the Natsal-2 ethnic minor-
ity boost. This has not influenced the estimate of the
prevalence of EC use in the past year for 1999–2001. Of
the 5842 women aged 16–44 years interviewed for Natsal-
3, 4889 (85%) reported at least one male sexual partner in
the past year, of whom 4825 had complete data on EC
use.
In 2010–12, 3.6% of women reported having used EC in
the past year, compared with 2.3% in 1999–2001 (Table 1).
The increase between the two time periods was statistically
significant (P = 0.0019). There was a strong age gradient in
both 1999–2001 and 2010–12, with use among 16–
24 year olds being considerably higher than among women
aged 40–44 years.
In both 1999–2001 and 2010–12, EC use was more com-
monly reported by those previously or never married than
by those married or cohabiting. Use increased significantly
over the period among those previously or never married
(P = 0.0024), but not among married or cohabiting
women. There was no consistent variation in EC use by
area-related deprivation level; however, an increase in use
between the two time periods was seen for women living in
areas in the two most deprived quintiles of area-related
deprivation, but not among women from other socio-eco-
nomic areas.
The use of EC was more commonly reported among
women studying for, or having attained, educational quali-
fications, beyond those minimally gained at age 16 years,
in both time periods, but this difference was only signifi-
cant in 2010–12. Furthermore, it was only in the highest
category of educational attainment that there was a signifi-
cant increase in use over the period. With regards to eth-
nicity, the proportion of EC users in 1999–2001 was
highest among women self-identifying as Asian, whereas in
2010–12 it was highest among women self-identifying as
black or ‘other’ (mixed, Chinese, or other). Age-adjusted
odds ratios (aORs) for increase in use were only signifi-
cantly raised over time for women in the ‘white’
(aOR 1.52; 95% CI 1.14–2.02; P = 0.0040) and ‘other’
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(aOR 3.71; 95% CI 1.03–13.43; P = 0.0445) ethnic groups,
but small numbers in some ethnic categories caution
against over-interpretation.
In terms of sexual risk behaviour, the prevalence of EC
use was higher among women who reported abortion
within the last 5 years, among women with more than one
Table 1. Use of EC in past year among sexually active women aged 16–44 years by demographic characteristics: 1999–2001 and 2010–2012
1999–2001 2010–2012 Age-
adjusted
OR
95% CI P
Denominators
(unweighted,
weighted)
Percentage (95% CI) Denominators
(unweighted,
weighted)
Percentage (95% CI)
Total 5430, 4859 2.30 (1.9–2.8) 4825, 3375 3.60 (3.0–4.3) 1.54 (1.17–2.02) 0.0019
Age group
16–24 years 1110, 1158 5.20 (4.0–6.9) 1604, 888 7.10 (5.7–8.9) 1.39 (0.95–2.03) 0.0887
25–29 years 1064, 870 2.40 (1.7–3.6) 1257, 624 5.10 (3.7–7.1) 2.16 (1.29–3.61) 0.0035
30–39 years 2324, 1988 1.50 (1.0–2.2) 1460, 1204 1.60 (1.1–2.3) 1.08 (0.62–1.88) 0.7907
40–44 years* 932, 843 0.10 (0.0–0.5) 504, 659 1.10 (0.5–2.5) 8.10 (1.57–41.75) 0.0124
Ethnic origin
White 4897, 4501 2.20 (1.8–2.7) 4245, 2929 3.30 (2.7–4.0) 1.52 (1.14–2.02) 0.0040
Asian/Asian British 144, 127 6.50 (2.6–15.1) 230, 194 3.30 (1.7–6.3) 0.49 (0.15–1.57) 0.2311
Black/Black British 209, 109 2.80 (0.8–9.0) 148, 117 8.30 (4.4–15.3) 3.20 (0.78–13.18) 0.1057
Other** 169, 112 2.30 (0.8–6.6) 157, 106 8.00 (4.2–14.5) 3.71 (1.03–13.43) 0.0445
Relationship status
Married/cohabiting 3345, 3351 1.20 (0.9–1.7) 2381, 2060 1.10 (0.8–1.6) 0.98 (0.59–1.62) 0.9393
Previously/never
married
2079, 1503 4.70 (3.7–5.9) 2433, 1308 7.50 (6.2–9.1) 1.64 (1.19–2.26) 0.0024
Religiosity***
No 856, 795 2.00 (1.2–3.6) 527, 369 2.80 (1.6–4.8) 1.27 (0.53–3.04) 0.5943
Yes 1074, 892 1.90 (1.2–3.2) 892, 716 3.80 (2.4–6.0) 1.82 (0.91–3.64) 0.0913
Academic qualifications****
No academic
qualifications
829, 714 1.00 (0.5–2.2) 401, 259 1.80 (0.8–3.7) 1.54 (0.52–4.53) 0.4346
Academic
qualifications
typically gained at
age 16*****
2396, 2185 1.90 (1.4–2.6) 1626, 1141 2.30 (1.7–3.1) 1.29 (0.82–2.02) 0.2703
Studying for/
attained
further academic
qualifications
2043, 1800 3.30 (2.4–4.4) 2545, 1810 4.80 (3.9–6.0) 1.51 (1.04–2.20) 0.0308
Index of multiple deprivation******
(least deprived) 792, 741 1.80 (1.0–3.2) 797, 596 3.30 (2.2–4.8) 1.82 (0.88–3.74) 0.1045
2 817, 788 3.10 (2.0–4.7) 860, 642 3.30 (2.3–4.9) 0.98 (0.53–1.82) 0.9570
3 880, 856 2.90 (1.8–4.7) 948, 676 3.10 (2.2–4.4) 0.99 (0.54–1.81) 0.9683
4 1230, 1123 2.50 (1.6–3.7) 1071, 744 4.40 (3.0–6.5) 1.83 (1.03–3.27) 0.0399
(most deprived) 1711, 1351 1.70 (1.1–2.6) 1149, 718 3.70 (2.7–5.2) 2.26 (1.29–3.96) 0.0045
*Significant age group/survey interaction, indicating that the change has been significantly different among those age 40–44 years relative to
those aged 16–24 years.
**Combines those reporting mixed, Chinese, or other ethnic origins because of the small number of participants reporting these ethnic origins.
***Religiosity was derived from self-reported importance of religion and religious beliefs now, and frequency of attendance at religious services
or meetings. Religiosity was defined as reporting that religion was very important or fairly important, with attendance at religious services or
meetings at least twice a year.
****Participants aged ≥17 years.
*****English General Certificate of Secondary Education or equivalent.
******Index of Multiple Deprivation (IMD) is a multi-dimensional measure of area (neighbourhood)-level deprivation based on the participant’s
postcode. IMD scores for England, Scotland, and Wales were adjusted before being combined and assigned to quintiles, using a method by Payne
and Abel.
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sexual partner in the past year, and among women who
attended a sexual health clinic in the past year for both
time periods (Table 2). It was significantly associated with
both STI diagnosis in the past year and higher than recom-
mended alcohol consumption in 2010–12, but not in 1999–
2001. In neither time frame was EC significantly associated
with intercourse before the age of 16 years. The confidence
intervals suggest that the association with the use of a less
reliable or no contraception was not significant in 1999–
2001, and barely reached significance in 2010–12 (Table 2).
The increase in use of EC between the two time periods
was associated appreciably with some, but not all, risk fac-
tors for unplanned pregnancy. A significant increase in use
was seen in 2010–12 among women with two or more sex-
ual partners in the past year (aOR 2.09; 95% CI 1.36–3.23;
P = 0.0009). A significant increase in use was also seen in
the more recent time period among women using a less
reliable method of contraception or none (aOR 1.93;
95% CI 1.29–2.88; P = 0.0013; Table 2). For other risk fac-
tors, however, such as abortion in the last 5 years or
heterosexual sex before the age of 16 years, the increase in
the use of EC was greater among women who did not
report these, than among those who did. EC use increased
significantly between the surveys among women whose first
intercourse occurred at age 16 years or later, but not
among women who were sexually active before the age of
16 years; it increased significantly among women who had
no experience of abortion in the past 5 years, but not
among women who did; and an increase was seen among
women who were not diagnosed with an STI in the past
year, but not among those who were.
In terms of health service attendance, there was higher
prevalence of EC use among women who usually sourced
their contraceptive supplies from clinical services com-
pared with retail sources in 1999–2001. This pattern was
reversed in 2010–12, when the proportion of women
using EC in the past year was higher among women using
retail sources compared with women using clinical sources
(0.8 versus 3.9% in 1999–2001; 6.0 versus 4.9% in 2010–
12). Age-adjusted odds show that EC use increased
between the two time periods among users of retail
sources of contraception (aOR 8.43; 95% CI 2.76–25.78;
P = 0.0002), whereas the increase among users of clinical
services barely reached significance (aOR 1.29; 95% CI
0.96–1.74; P = 0.0579).
Discussion
Main findings
These data from two serially conducted national probability
sample surveys show a small but significant increase in EC
use among heterosexually active women aged 16–44 years
in Britain in the first decade of the 21st century. Our data
show that that this increase was considerably greater among
women routinely using retail outlets for contraceptive sup-
plies than among women using clinical services. The
increase in use of EC has also been greater among women
who live in less affluent areas and also among those who
are currently single. In terms of risk factors for unplanned
pregnancy, the picture is more mixed. We saw a sizeable
increase in the use of EC in the last survey among women
using less effective methods of contraception, such that EC
use is now more common among this group than among
women with higher levels of contraceptive protection. At
the same time, although prevalence of EC use was higher
among women who had an abortion in the preceding 5-
year period, the increase in use over time was larger among
those who had not undergone abortion. Furthermore, asso-
ciations with EC use are generally stronger, and the
increase in prevalence is generally greater, for indicators of
STI risk (multiple sexual partners and STI diagnosis) than
for indicators of risk of unplanned pregnancy (abortion
and earlier sexual experience).
Strengths and limitations
This large-scale, population-based study has advantages
over the use of routine data in measuring changes in pat-
terns of EC use over time, notably our ability to describe
the changing characteristics of EC users. Nevertheless, even
in a sample of this size, the relative rarity of some experi-
ences – an STI diagnosis, for example – limit the extent to
which we are able to detect significant associations. A fur-
ther limitation results from the cross-sectional nature of
the study, such that causal direction cannot be established.
We cannot know, for example, whether the start of use of
the current contraceptive method preceded EC use or was
subsequent to it, and this hampers interpretation.
Interpretation
One of the most striking findings of the study, an eight-
fold increase in EC use between the time periods among
women using retail sources to obtain contraception, is con-
firmed in routinely collected prescription NHS data. EC
prescriptions dispensed from sexual and reproductive
health services as well as clinical community sources (pre-
dominantly general practitioners) has been falling during
the period under study, such that in 2012–13 the number
of prescriptions for oral EC was less than half that in
2000–01.23 Furthermore, the Office of National Statistics
reported in 2003–04 that 27% of women obtained their EC
from community pharmacies, and by 2007–08 this had
risen to 51%.24,25 These data point to a shift to over-the-
counter access coinciding with the deregulation of EC sup-
ply in Britain. A study spanning the period of pharmacy
deregulation in France reported that, by 2004, most women
(60.1%) stated that the last time that they used oral EC
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they obtained it directly from the pharmacy without a pre-
scription.26
Although the increase in use of EC apparently coinciding
with deregulation is to be welcomed, our data do not fully
support the view that the concomitant increase in uptake
has been greatest among those at highest risk of unplanned
pregnancy. Studies have highlighted several potential
limitations of pharmacy supply compared with access to
clinical services. This suggests that barriers for access to EC
remain for some women, possibly related to a lack of
knowledge about EC and/or a lack of ease in requesting the
medication.27
Effective targeting of women most at risk of unplanned
pregnancy is one challenge to be overcome in the phar-
macy supply of EC. There is some evidence of deficiencies
in the provision of information about contraceptive meth-
ods at the time of obtaining EC in pharmacies,28,29
although larger, population-based studies have not shown
Table 2. Use of EC in past year among sexually active women aged 16–44 years by behavioural characteristics: 1999–2001 and 2010–2012
1999–2001 2010–2012 Age-
adjusted
OR for
change
over time
(95% CI) P
Denominators Percentage (95% CI) Denominators Percentage (95% CI)
Total 5430, 4859 2.30 (1.9–2.8) 4825, 3375 3.60 (3.0–4.3) 1.54 (1.17–2.02) 0.0019
Heterosexual intercourse before age 16 years
No 4257, 3792 2.00 (1.6–2.6) 3347, 2493 3.40 (2.7–4.2) 1.68 (1.21–2.35) 0.0021
Yes 1172, 1066 3.40 (2.3–4.9) 1478, 882 4.30 (3.3–5.6) 1.29 (0.80–2.08) 0.2968
Abortion in the past 5 years
No 5024, 4544 2.10 (1.7–2.6) 4489, 3196 3.40 (2.8–4.1) 1.57 (1.17–2.12) 0.0029
Yes 398, 311 5.30 (3.2–8.5) 320, 170 7.90 (5.2–11.8) 1.53 (0.78–2.98) 0.2141
Number of sexual partners in the past year
1 4468, 4093 1.70 (1.4–2.3) 3731, 2756 1.90 (1.6–2.4) 1.10 (0.78–1.57) 0.5761
2 or more* 927, 738 5.50 (4.0–7.6) 1092, 619 11.00 (8.6–13.9) 2.09 (1.36–3.23) 0.0009
Diagnosed with an STI in the past year**
No 5119, 4615 2.30 (1.9–2.8) 4694, 3303 3.40 (2.9–4.0) 1.49 (1.13–1.96) 0.0050
Yes 86, 73 3.50 (0.9–11.8) 103, 56 14.90 (7.0–28.7) 4.56 (0.95–22.03) 0.0568
Attended a sexual health clinic in the past year
No 5273, 4746 2.20 (1.8–2.7) 4209, 3025 2.80 (2.3–3.4) 1.33 (0.99–1.78) 0.0579
Yes 152, 110 6.90 (3.6–12.9) 565, 319 11.70 (8.5–15.8) 1.68 (0.75–3.76) 0.2045
Usual contraceptive method, past year***
Reliable method 3018, 2770 2.10 (1.6–2.8) 2808, 1902 2.90 (2.3–3.7) 1.31 (0.90–1.91) 0.1577
Less reliable or
no method
2207, 1911 2.30 (1.7–3.2) 2011, 1469 4.40 (3.4–5.6) 1.93 (1.29–2.88) 0.0013
Source of contraceptive supplies, past year
Not got
contraceptive
supplies
1873, 1709 0.20 (0.1–0.6) 655, 594 1.10 (0.5–2.1) 4.16 (1.22–14.21) 0.0229
Clinical 3052, 2702 3.90 (3.2–4.8) 2967, 1862 4.90 (4.0–6.0) 1.29 (0.96–1.74) 0.0907
Retail/Other 505, 448 0.80 (0.3–2.2) 505, 390 6.00 (4.2–8.5) 8.43 (2.76–25.78) 0.0002
Average alcohol consumption per week
None/Not more
than
recommended
4865, 4361 2.10 (1.7–2.6) 4196, 2959 3.10 (2.6–3.8) 1.44 (1.08–1.93) 0.0139
More than
recommended
563, 496 3.90 (2.3–6.5) 607, 404 7.00 (4.6–10.5) 1.89 (0.94–3.79) 0.0724
*Significant number of sexual partners/survey interaction indicating that the change has been significantly different among those reporting two or
more sexual partners in the past year, relative to those reporting.
**Chlamydia, gonorrhoea, syphilis, herpes, genital warts, trichomonas, or non-gonococcal urethritis.
***Reported usual method of contraception used in the past year was classified according the most effective method reported. Methods with a
typical use failure rate (including incorrect and inconsistent use) below 10% were classified as more effective [IUD, intrauterine systems (IUS),
implant, injection, patch, and oral contraceptive pill]. Those with a typical use failure rate of more than 10% were classified as less effective
[condoms (male and female), diaphragm, pessaries, gels, EC, withdrawal, rhythm method, and no method].
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an adverse effect on contraceptive uptake of greater EC
access through pharmacies. Women obtaining EC through
pharmacies in France, for example, were no less likely to
use more effective methods of contraception than women
obtaining it from clinical sources.26 Nevertheless, the phar-
macy encounter is a potential opportunity to provide infor-
mation about contraception, and in a recent pilot study of
pharmacy provision of oral contraception in South Lon-
don, the pharmacy supplying the highest number of pill
prescriptions also saw a significant fall in requests for EC,
although this finding was not consistent across all outlets.29
Conclusion
This study has provided information on changing patterns
of EC use. The increased prevalence of use among women
with some risk factors, but not all, suggests that despite
deregulation, barriers to access remain. We highlight the
importance of strategies to ensure that women are provided
with information at the point of supply that allows them
to make informed choices about their continuing contra-
ceptive needs.
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